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Abstract 
Bovine colostrum is the first milk secreted by cows after calving. Even though bovine 
colostrum has similar protein content as regular milk, it contains greater levels of anti-microbial 
substances and growth factors. Intense training may compromise the immune system; therefore, 
colostrum has potential to improve exercise performance by preventing immune system 
dysfunction that is common during periods of intense training.  
PURPOSE: The purpose was to determine the effect of 8 weeks of bovine colostrum 
supplementation in comparison to soy protein supplementation, on rugby players’: body 
composition, strength, endurance performance, vertical jump height, and IgA, IL-6, IL-1β and C 
reactive protein levels, during the regular rugby union season.  
METHODS: Twenty-nine rugby union players (n=3 female) were randomized into two 
groups (double blind); Group 1 received 38g/d of protein from bovine colostrum, and Group 2 
received 38g/d of protein from soy. Before and after the 8 weeks of supplementation, participants 
were evaluated for IgA, IL-6, IL-1β and C reactive protein levels from salivary samples, body 
composition using dual energy X-ray absorptiometry, muscle thickness of their quadriceps and 
biceps using ultrasound, bench press and leg press strength, vertical jump height, and aerobic 
fitness using the Leger maximal multistage 20-m shuttle run field test.  
RESULTS: There were no differences between groups over time in all variables other than 
vertical jump height. There was a significant group x time interaction for vertical jump (p=0.002) 
with the colostrum group (+0.9cm) increasing more than the soy group (-0.5cm).  
CONCLUSION: BC supplementation in rugby union players during the regular season did 
not affect body composition, salivary immune markers level and fitness components (excluding 
vertical jump height) in comparison to soy protein supplementation. Bovine colostrum 
supplementation may enhance leg power to a greater extent than soy protein supplementation.  
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1. Scientific Framework 
1.1 Introduction  
1.1.1 Bovine Colostrum 
Bovine colostrum (BC) is the first milk secreted by cows after calving. Even though BC 
has similar protein content as regular milk, it contains greater levels of anti-microbial substances 
and growth factors (Donavan and Odle 1994; Mero et al. 2002). The main growth factor in BC is 
insulin-like growth factor-1 (Francis et al. 1988) which stimulates growth of muscle tissue 
(Tomas et al. 1991) and is important in maintaining muscle mass and function in adults (Borst et 
al. 2001).  One of the main anti-microbial substances in BC is immunoglobulin A (IgA). IgA 
levels in BC are approximately a hundredfold higher than in regular milk (Mach and Pahud 
1971). Other anti-microbial substances that are much higher in BC than in regular milk are 
proteins and peptides such as lysozyme and lactoferrin (Korhonen 1977; Shing et al. 2009) 
which are essential for proper immune system function. 
Previous studies have shown improvements in body composition (Antonio et al. 2001), 
power (Buckley et al. 2003; Hofman et al. 2002), and strength (Duff et al. 2014), when BC 
supplementation was used during a resistance training program. The mechanism through which 
BC acts to benefit performance and body composition, remains unclear. 
 
1.1.2 Rugby 
Rugby is an intermittent contact team sport with periods of high-intensity activity (running, 
tackling) and low-intensity recovery (walking, jogging, and standing) taking place over two 40-
minute halves with a 10-minute half time interval. The physiological demands of rugby union are 
complex when compared with individual sports (e.g. running, cycling, and swimming).  
Mean heart rates of 82% to 84% of maximum heart rate have been reported for elite 
players during competitive matches (Twist and Highton 2013). Moreover, players were shown to 
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spend a considerable percentage (30-44%) of total match-play in high-intensity activities with 
the mean intensity of semi-professional matches reported to be 81% VO2max (Gabbett 2007). A 
high VO2max facilitates the repetition of high-intensity efforts, and is related to the distance 
covered, level of work intensity, number of sprints, and involvements with the ball (Duthie et al. 
2003). Duthie et al. (2003) concluded that the energy contributions during the work periods in 
intermittent team games, such as rugby, are mainly anaerobic. The mean blood lactate 
concentrations during competition for semi-professional rugby league, was found to be 7.2 
mmol/L (Coutts et al. 2003). 
Rugby performance requires high levels of muscular strength and power for success, 
particularly in the execution of tackles, explosive acceleration, scrummaging (when players are 
packing closely together with their heads down and attempting to gain possession of the ball), 
and forceful play during rucking (a ruck is formed when one player or more, from each team, 
bind onto each other with the ball on the ground between them) and mauling (a maul is formed 
when the ball carrier is being held by the opponents, and one or more of his team mates, bind to 
him. The mean force that one team produces during scrummaging, ranges from 6210 to 9090 N 
(O’Gorman et al. 2000). These findings led Twist and Highton (2003) to conclude that rugby 
places considerable physiological demands on both the aerobic and anaerobic energy systems. 
The demands required during a rugby game can lead to fatigue, tiredness and decrements in 
muscle performance and function. Gabbett (2005) and Schneider et al. (1998) found that teams’ 
in-season training programs, emphasize skills (catching, ball-carrying, etc.), speed, agility, and 
aerobic training, while neglecting strength training. This may increase the loss of lean tissue 
mass and strength, resulting in a greater injury risk (Gabbett 2005).   
Understanding the nutritional needs of rugby players is very important in order to optimize 
performance and recovery (Casiero 2013). The amount of carbohydrate that rugby players 
require is between 5 to 8 g/day, per kilogram of body mass (Casiero 2013; Kreider et al. 2010). 
In addition, it is also recommended that the source of 20% to 30% of rugby players’ total daily 
caloric intake, should be fat (Venkatraman and Pendergast 2000). Rugby players also require 
more protein than the average population, in order to support muscle growth and improve 
recovery (Casiero 2013). It was recommended that rugby players should consume twice the 
recommended daily allowance of protein (1.5- 2 g/day per kg, instead of 0.75-1 g/day per kg), in 
order to prevent a negative nitrogen balance (Chesley et al. 1992; Lemon et al. 1992; 
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Tarnopolsky et al. 1988), which may impair performance and slow recovery (Leutholtz and 
Kreider 2001). The type of protein is also important, as casein and whey proteins for example 
display different rates of digestion and absorption, and are beneficial for decreasing whole body 
catabolism (Boirie at al. 1996). Hence, Casiero (2013) suggested that rugby players should be 
encouraged to eat not only an adequate amount of protein, but also protein from quality sources 
such as chicken, milk, eggs and fish. 
Supplements also play a role in rugby players’ nutrition. One of the main supplements 
being used is creatine monohydrate, which has been shown to increase muscular endurance in 
rugby players (Chilibeck et al. 2007), and high intensity exercise capacity and lean muscle mass 
in other athletes (Kreider et al. 2010). Another popular supplement among rugby players is 
caffeine, which enhances sport performance when consumed in low to moderate doses (3 to 6 mg 
per kg) (Goldstein et al. 2010). Caffeine is also beneficial for high intensity exercise of 
prolonged duration in team sports (Schneiker et al. 2006). 
Intense training, as in rugby, can also compromise the immune system. Neutrophil 
function, immunoglobulins concentrations and Natural killer cell number are all suppressed 
during prolonged periods of intense exercise training (MacKinnon 2000). Therefore, BC has 
potential to improve fitness, possibly by preventing immune system dysfunction that is common 
during periods of intense training (Shing et al. 2009). 
 
1.2 Literature Review 
The first study to investigate the effect of BC supplementation on exercise performance 
was Mero et al. in 1997. Since then, research has investigated the ability of BC supplementation 
to improve body composition, strength, endurance, anaerobic performance, power, and immune 
system functioning. In addition, researchers are also trying to determine mechanisms for these 
improvements. 
 
1.2.1 Body Composition and Strength 
The evidence, in regards to the effect of BC supplementation on body composition and 
strength, is contradictory. Two studies, using doses of 20-60 g/day during 8 weeks of training 
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found no improvement in strength with BC supplementation: Antonio et al. (2001) used a dose of 
20 g/day in 22 active participants, who followed a 3 days a week resistance training program, 
and Buckley et al. (2003) used a dose of 60 g/day in 51 “active” males, who followed a 6 days a 
week alternate resistant training and plyometric training program. On the other hand, two other 
studies found that BC supplementation with a dose of 60 g/day improved strength after 8 or more 
weeks of training: Kerksick et al. (2001) used a population of 49 “resistance trained” participants 
who followed a 4 days per week resistance training program (for 12 weeks), and Duff et al. 
(2014) used a population of 40 older adults who followed a 3 days per week resistance training 
program (for 8 weeks). 
A similar inconsistency can be found in regards to the effect of BC supplementation on 
body composition. While Duff et al. (2014) did not find any significant differences in body 
composition (measured by Dual-energy X-ray absorptiometry) between their BC group and the 
control (whey) group (using a dose of 60 g/day), Antonio et al. (2001) found a significant 
difference in lean tissue mass, between their BC group and a control group (in favor of the BC 
group) even though they used a lower dosage of 20 g/day. In addition, Brinkworth et al. (2004) 
found a significant change in lean tissue mass (greater cross sectional area in the upper arm 
muscles) in favor of BC supplementation of 60 g/day, versus placebo, after 8 weeks of 
supplementation and strength training for 4 days a week. One possible reason for this 
inconsistency might be the fact that the participants in the Duff et al. study were elderly, while 
the participants in the other studies were young and physically active, and thus, may be more 
able to a change body composition. 
To sum up, from the limited amount of previous work, there is no conclusive evidence for 
BC supplementation to affect body composition or strength. In addition, it seems that higher 
doses of BC are required in order to notice an effect. Using a higher dose of 60 g/day of BC 
would help in maximizing and detecting the effect, if there is one. On the other hand, higher 
doses of more than 60 g/day of BC may decrease compliance, as it will require participants to 
ingest bigger serving sizes, and/or increase the ingesting frequency. 
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1.2.2 Power 
 Power (“explosiveness”) is the rate at which mechanical work is done (i.e. the product of 
force and velocity) and it is a very important quality in athletes’ performance, especially in sports 
such as football, rugby, weightlifting, etc. (Winter and Fowler, 2009). BC supplementation in 
athletes, at a dose of 60 g/day, for 8 weeks during training improved vertical jump height (an 
indirect measurement of power) and peak cycle power, in comparison to supplementation with 
placebo or whey (Leppäluoto et al. 2000; Buckley et al. 2003). However, while these findings 
might suggest that BC is beneficial to power activities, Leppäluoto et al. (2000) did not report the 
details of training and diet control (which might be confounders), and what is more, another 
study involving a similar dosage (60 g/day) and duration (8 weeks), showed no improvement in 
vertical jump performance in athletes who received BC supplementation (Hofman et al. 2002). 
Therefore, limited conclusions can be drawn in regards to the effect of BC supplementation on 
power, as prior evidence is far from being conclusive. 
 
1.2.3 Anaerobic Performance 
Anaerobic glycolysis results in the production of H+ and lactate. Buffer capacity is the 
ability to bind free protons (i.e. to buffer H+), and offset reductions in pH during exercise; hence, 
given the strong association between acidosis and muscular fatigue, buffer capacity is an 
important attribute for maintaining anaerobic performance (Parkhouse and McKenzie 1984).  
The main buffers of H+ come from skeletal muscle and include protein, inorganic phosphate, and 
phosphocreatine. Other components in blood including haemoglobin, bicarbonate and plasma 
proteins also buffer H+. Brinkworth et al. (2002) examined whether BC supplementation of 60 
g/day (vs. whey) could enhance the buffering of H+, in response to a 9-week training program. 
Two incremental rowing tests on a rowing ergometer (consisting of 3 x 4 minute submaximal 
workloads and a 4 minute maximal effort, each separated by a 1 minute recovery) were used to 
assess performance, before and after the completion of the supplementation period. Buffering 
capacity was estimated from the differences in the blood lactate levels and the blood pH levels, 
which were taken at the end of each workload during the testing period. It was found that 
buffering capacity was significantly increased after BC supplementation versus whey. From the 
findings of a following study (Brinkworth and Buckley, 2004), it was determined that the 
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difference is the result of enhanced muscle buffering capacity, and not haemoglobin levels, 
plasma bicarbonate levels, or plasma buffering capacity in general. 
Other studies measured anaerobic performance in athletes in a more practical way, 
measuring performance variables, in the athletes’ “natural” environment. The findings from 
these studies seem to contradict each other. While Hofman et al. (2002) found that a 
supplementation of 60 g/day BC for 8 weeks significantly improved repeated sprint running 
performance (in comparison to placebo), Shing et al. (2006) found no improvement in a time-to-
fatigue test at 110% of ventilatory threshold, between BC and placebo in 29 highly trained male 
road cyclists. It is important to note that Shing et al. (2006) used a lower dosage of 10 g/day of 
BC, which may not be sufficient to produce a measurable effect. On the other hand, another 
study, using a higher dosage of 60 g/day of BC also found no significant difference (vs. placebo) 
in cyclists’ anaerobic performance (Buckley et al. 2003). 
In sum, it appears that there is inconsistency in the evidence for the positive effect of BC 
supplementation on anaerobic performance. Also, if a positive effect of BC supplementation on 
anaerobic performance does exist, the mechanism for this effect is yet to be determined. 
 
1.2.4 Endurance Performance 
Endurance performance (i.e., aerobic fitness) refers to the use of oxygen to adequately 
meet energy demands during exercise via aerobic metabolism. Endurance performance is crucial 
in sports such as long distance running/walking, long distance swimming, cycling, soccer, and 
rugby. One possible mechanism for the potential positive effect of BC on aerobic fitness is an 
improved muscle glycogen resynthesis (Shing et al. 2009). Although increased muscle glycogen 
levels during normal training do not improve endurance performance (Hawley et al. 1997), 
during repeated days of high-intensity exercise, increased muscle glycogen levels may prevent 
and delay fatigue (Kavouras et al. 2004; McInerney et al. 2005). Eight weeks of BC 
supplementation in dosages ranging from 10-60 g/day improved aerobic performance (in 
comparison to whey or placebo): Coombes et al. (2002) assessed 42 professional cyclists who 
consumed either 20 or 60 g/day (significant differences were found with both doses vs. whey), 
while Shing et al. (2006) used 29 professional cyclists who consumed 10 g/day of BC for eight 
weeks (vs. placebo). BC supplementation may improve glycogen levels by enhancing the activity 
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of some of the enzymes involved in gluconeogenesis (and therefore perhaps synthesis of 
glycogen), as it was shown that colostrum feeding in calves enhanced activity of the rate-limiting 
enzymes for gluconeogenesis, pyruvate carboxylase and phosphoenolpyruvate carboxykinase 
(Hammon et al. 2003).  
Another possible mechanism for the positive effect of BC supplementation on aerobic 
performance may be that it prevents the decrease in testosterone concentration during long-
duration exercise and therefore improves protein synthesis or prevents protein catabolism during 
endurance training (Shing et al. 2013). In addition, some of the growth factors found in BC may 
enhance nutrient uptake from the intestine; this has been suggested as another possible mediator 
to improve adaptation to intense aerobic training (Coombes et al. 2002). BC may also have direct 
effects on cardiovascular functioning: eliciting lower heart rate, higher cardiac output, and 
elevated parasympathetic indices of heart rate variability (i.e., increased intervals between two 
consecutive R waves in the ECG) (Shing et al. 2013). 
Overall, it appears that BC supplementation is likely to improve endurance performance. 
However, the mechanism by which BC acts to improve endurance performance is yet to be 
definitively determined. While the above- suggested mechanisms (improved muscle glycogen 
resynthesis, enhanced nutrient absorption) may be possible, alterations in respiratory exchange 
ratio (alterations in the oxidation of carbohydrate vs. fat), lactate threshold or insulin like growth 
factor 1 (IGF-1) levels have been ruled out (Shing et al. 2009). 
 
1.2.5 Immune Function 
Intense exercise suppresses immunity for several hours (Nieman 2002). Hence, athletes 
that perform high intensity training are at a high risk for over-training syndrome (Halson et al. 
2002; Halson et al. 2003; Mackinnon 2000) and upper respiratory tract infections (Mackinnon 
2000; Fitzgerald 1991). Over-training syndrome is a neuroendocrine disorder characterized by 
poor performance in competition, inability to maintain training loads, persistent fatigue, reduced 
catecholamine excretion, frequent illness, disturbed sleep and alterations in mood state 
(Mackinnon 2000). It is estimated that, at any given time, between 7 and 20% of all athletes may 
exhibit symptoms of overtraining syndrome. Overtraining syndrome can be due to excessively 
large volumes of training, without adequate rest and recovery (Mackinnon 2000). 
8 
 
There are a large number of markers of immune function that one can measure from blood 
or saliva samples. The markers that were chosen for assessment in this thesis are reviewed in the 
following section. 
 
1.2.5.1 Immune Function Markers 
1.2.5.1.1 Immunoglobulin A (IgA) 
 Immunoglobulin A (IgA) plays key roles in immune protection while being a major serum 
immunoglobulin and the main antibody class in the external secretions that immerse mucosal 
surfaces (Woof and Kerr 2006). An immunoglobulin (also known as an antibody), is a Y-shape 
protein produced by plasma cells that is used by the immune system to identify and neutralize 
pathogens such as bacteria and viruses.   
A substantial amount of energy is expended in the production of IgA. This amount of 
energy exceeds the amount of energy that is required for the production of all the other antibody 
classes combined. This may suggest that the benefits provided by IgA, in terms of immune 
defence, must be substantial (Woof and Kerr 2006).   
IgA protects the vast surface area occupied by mucosal surfaces, such as the linings of the 
respiratory, gastrointestinal, and genitourinary tracts. As the major class of antibody present at 
these sites and by being the first line of defence against many invading pathogens, IgA is 
considered very important to maintain proper function of the innate immune system (Woof and 
Kerr 2006). This system is an important subsystem of the overall immune system that comprises 
the cells that defend from infection. Unlike the adaptive immune system, it does not give long-
lasting immunity to the host, but an immediate defense against an infection.  
It seems that the very high concentration of secretory IgA in human (and other mammals) 
colostrum and milk, strongly suggests that IgA must play a crucial role in the passive immune 
protection of the newborn (Woof and Kerr 2006). 
 
1.2.5.1.2 C-reactive protein (CRP)  
C-reactive protein (CRP) was discovered by Tillett and Francis in 1930 as a substance in 
the serum of patients with acute inflammation that reacted with the C polysaccharide of 
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pneumococcus. CRP interacts with the complement system to activate an immunologic defense 
mechanism. The complement system is a group of proteins that move freely throughout the 
bloodstream. They work with the immune system and play a role in the development of 
inflammation. Synthesis of CRP occurs in hepatocytes  and  is regulated  primarily  by the 
proinflammatory cytokines: interleukin-1β,  interleukin-6,  and  tumor  necrosis  factor-α (Ingle 
and Patel 2011). 
CRP has a normal range in the blood of < 2 mg/L.  In populations with illnesses such as 
rheumatoid arthritis or sepsis, the concentrations can increase up to 300 mg/L (Ingle and Patel 
2011). In athletes, CRP levels are increased when overtraining syndrome, or tissue injury have 
occurred (Smith 2004). 
 
1.2.5.1.3 Interleukin 1 beta (IL-1β) and Interleukin 6 (IL-6) 
Interleukin 1 beta (IL-1β) and Interleukin 6 (IL-6) are pro-inflammatory cytokines. The 
injection of them (in order to mimic secretion) into animals or humans, was shown to produce 
the acute phase inflammation response; these cytokines facilitate an influx of lymphocytes, 
neutrophils, monocytes and other cells, which participate in the clearing of antigens and healing 
of tissue (Ostrowski et al. 1999). 
Both IL-1β and IL-6 levels are elevated in the circulation after an acute exercise. Although 
IL-1β is elevated for only a few hours post exercise, it has also been proposed to mediate 
anabolic and catabolic processes that can last for several days (Pedersen et al. 2004). The IL-6 
also acts as an energy sensor, being dependent on the glycogen content in the muscle; it is 
released from contracting muscles in high amounts and it induces lipolysis (Pedersen et al. 
2004). 
 
1.2.5.2 Bovine Colostrum, Exercise, and Immune Function 
There is evidence that several immune parameters are suppressed during prolonged periods 
of intense exercise training. These include neutrophil function, serum and salivary IgA 
concentrations, and natural killer cell number (Mackinnon 2000). It has also been proposed that 
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the physical stress of intense exercise training initially causes elevation of stress hormone levels, 
such as CRP (Smith 2004), catecholamines and glucocorticoids (Urhausen et al. 1995).  
Cytokines have also been proposed as mediators of overtraining syndrome. Repetitive, 
high volume exercise with inadequate rest causes injury (microtrauma) to joints, muscles and 
connective tissue. This injury in turn activates monocytes to produce and release inflammatory 
cytokines such as IL-1b, IL-6 and TNF-a (a cytokine that is involved in an acute systemic 
inflammation), initiating chronic systemic inflammation and suppressed immune function (Shing 
et al. 2009).  
Although lymphocytes levels are not different between rest and overtraining syndrome, 
lymphocytes may be activated to a greater extent by periods of intense exercise training (Fry et 
al. 1992; Rhind et al. 1994). For example, expression of high-affinity IL-2 receptor was higher 
on cells in distance runners compared with matched non-runners (Rhind et al. 1994). In addition, 
a significant increase in low-affinity IL-2 receptor expression has been observed in cells obtained 
over 10 days of intense running training that caused overreaching, despite no changes in 
lymphocyte levels (Fry et al. 1992). 
A depressed immune system is associated with an increased risk of upper respiratory tract 
infection. One potentially beneficial effect of BC on immune function may be reduction in upper 
respiratory tract infection symptoms. It is thought that an increase in salivary IgA affords greater 
protection against upper respiratory tract infection (Shing et al. 2009). However, there is no ideal 
single marker to measure immune modulation following a nutrition intervention (Gleeson 2005).  
In infants, colostrum stimulates immune development through lymphoid tissue in the 
oropharynx and the gut. The absorption of the immunologic factors by the oral mucosa 
stimulates the immune system systemically, and promotes the mucosal differentiation in the gut, 
developing the protective gut immune barrier (Gephart & Weller, 2014). Interestingly, in preterm 
infants who cannot tolerate enteral feedings, and receive an oropharyngeal administration of 
colostrum (an intervention in which a small amount of colostrum is placed directly onto the 
oropharyngeal mucosa in the buccal cavity for absorption. This does not involve the infant’s 
swallowing of milk), the immune factors in colostrum still interact with lymphoid tissues in the 
oropharynx, and still stimulate the immature neonatal immune system. This finding may suggest 
that in absorption of immunologic factors from colostrum take place in other mucosal tissues, in 
addition to the gut (Lee et al. 2015). 
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A number of studies examined the effect of BC supplementation on IgA concentration. 
Some of these studies found no significant difference in IgA levels after supplementing with BC 
(Mero et al. 1997; Shing et al. 2007; Shing et al. 2013). However, Mero et al. (2002) and Crooks 
et al. (2006) who used 20 g/day for 2 weeks and 26 g/day for 12 weeks respectively, found a 
significant difference in IgA levels after supplementing with BC. The reason for this 
contradiction in findings could be that Mero et al. (1997) conducted their first study for 8 days 
only, a period of time which may be too short in order to present a significant effect, and that 
Shing et al. (2007; 2013) used a dosage of 10 g/day only, which may not be enough to create a 
detectable change in IgA levels. 
A few studies have also instigated the relationship between BC supplementation and upper 
respiratory tract infections. Brinkworth and Buckley (2003) found that the percentage of 
participants that had upper respiratory tract infections was significantly lower in a group who 
received BC (60 g/day for 8 weeks) compared to placebo. However, Crooks et al. (2006) found 
no significant difference in upper respiratory tract infections incidence, despite a significant 
increase in salivary IgA levels in the BC group (vs. whey). 
Again, although some studies suggest that BC supplementation may be associated with 
increased levels of IgA levels, there appears to be discrepancies in the research on the effect of 
BC supplementation on immune function and the possible mechanisms. 
 
1.2.6 Insulin-like Growth Factor-1 (IGF1) 
IGF-1 is a hormone that plays an important role in childhood growth and continues to have 
anabolic effects in adults. Despite the fact that BC contains IGF-1, only one group of authors 
(out of more than a dozen) reported significant increases in IGF-1 levels after BC 
supplementation for 8 and 14 days (Mero et al. 1997; Mero et al. 2002). IGF-1 is usually 
degraded in the gastrointestinal tract, but it was suggested that some factors in BC may improve 
the absorption of IGF-1 by preventing its breakdown (Playford et al. 1993). 
Normal IGF-1 levels for young adults are 14-48 nmol/L. The increase reported in the 
studies mentioned above, was approximately 5 nmol/L, while the amount of IGF-1 contained in 
the BC was 74 μg/day.  At this dose, if 65% of IGF-1 was absorbed, the concentration of IGF-1 
would only be expected to rise only by approximately 1.05 nmol/L. This suggests that the 
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increase in serum IGF-1 was probably due to an increase in endogenous production (Shing et al. 
2009). Other studies with similar doses of BC and longer supplementation periods, have reported 
no significant changes in IGF-1 levels following 4–8 weeks of BC supplementation (Buckley et 
al. 2003; Coombes et al. 2002). 
Given the fact that IGF-1 is usually degraded in the gastrointestinal tract, and that all 
studies but two (Mero et al. 1997; Mero et al. 2002) found no significant changes in the levels of 
IGF-1 after BC supplementation, it seems likely the possible positive effects of BC 
supplementation on body composition and/or fitness are not due to  IGF-1 levels. 
 
1.3 Purpose and Hypotheses: 
The purpose of the study is to determine the effect of 8 weeks of bovine colostrum 
supplementation in comparison to soy protein supplementation, on rugby players’: fitness, body 
composition, and IgA, IL-6, IL-1β and CRP levels, during the rugby season. We chose to focus 
on rugby union players, who undergo intense training programs during their playing season, as 
the physiological demands of rugby union are complex (all the components of fitness play a role; 
strength, power, anaerobic and aerobic fitness) in comparison to individual sports such as 
swimming, running, etc. This unique sport, with its many various physical demands, makes it 
possible to track and test multiple outcomes in the same study. In addition, intense training, as in 
rugby, can compromise the immune system. Therefore, rugby players would be a good 
population to examine the effect of BC on the immune system. 
It was hypothesized that BC supplementation would result in greater anabolic effects in 
response to intense training which would translate into more favorable changes in lean tissue 
mass, strength, jump height and aerobic performance, compared to soy protein.  
The secondary hypothesis was that BC supplementation would result in lower levels of 
salivary IL-6, IL-1b and CRP, and a higher level of salivary IgA, in comparison to soy 
supplementation. 
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2. Methodology 
2.1 Study Design and Intervention 
Twenty-nine rugby union players (n=3 women) were randomly assigned, by use of a 
computerized random number generator (1:1 allocation ratio), to receive 38g/day of protein from 
BC protein powder (63g of BC supplement) or soy protein powder (72g of soy supplement) 
which was used as control, for eight weeks during their rugby season.  
The study was double blinded: researchers, participants, and all individuals conducting 
outcome assessments were unaware of group assignments. Both groups were provided with a 5 
Litre container that included the supplement and a measuring scoop. Buckets were identical and 
the scoops were similar but different in size (volume). Blinding was accomplished using an 
individual, who was independent of the rest of the research team, to prepare the numbered 
buckets containing the supplement. BC was a heat-treated spray-dried, >25% IgG, commercially 
available product (trade-named Eterna Gold manufactured and marketed by the Saskatoon 
Colostrum Co. Ltd., Saskatoon, SK, Canada). BC was derived from first day postpartum excess 
colostrum collected from Canadian dairy cows and is licensed by Health Canada as a natural 
health product for immune system and athletic support (Natural Health Product Number 
80035324). Both supplements were flavourless, odorless, and had the same color, and texture.  
BC dose chosen was based on the effective dose for increasing lean tissue mass during 
strength training of young participants (Antonio et al. 2001, Kerksick et al. 2007), and increasing 
muscle strength in older participants (Duff et al. 2013). Soy protein was used as a control 
supplement because it matched the nitrogen (i.e. protein content) and caloric content of BC 
without delivering the same bioactive molecules found in BC (Table 2-1). Participants were to 
consume the supplement 3 times a day, with one time before a workout and another time 
immediately after a workout.  
During these 8 weeks, the players followed their regular season training routine, which 
consists of two 2-hour rugby practices per week and one 80-minute game. Participants also had 
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between two to three strength workouts a week. In order to control for training volume, players 
recorded their first and last week training regime and games (minutes) played. To assess dietary 
intake, three-day dietary records were collected at baseline and during the last week of 
supplementation, as three-day records were shown to produce the best agreement between 
reported and observed intakes (Crawford et al. 1994), and are considered to be an acceptable 
dietary assessment tool (Yang et al. 2010). Evaluation of nutrient intakes was derived from the 
US Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory, USDA 
National Nutrient Database for Standard Reference, Release 28, May 2016. This database is a 
major source of food composition data in the United States, and contains data on 8,789 food 
items and up to 150 food components. 
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*Values were analyzed by the Saskatoon Colostrum Company, and were calculated from Kehoe et al. (2007) 
reported at 27.6% total solids and assuming 1.06 g/ml (Christiansen 2010). 
 
Content in the daily dosage of 
BC dry powder (60g) 
Content in daily dosage of 
soy protein dry powder (72g) 
Calories (kcal) 284 262 
Fat (g) 9 1 
Saturated fat (g) 5 0 
Cholesterol (mg) 110 0 
Carbohydrate (g) 13 25 
Sugars (g) 5 11 
Protein (g) 38 38 
Calcium (mg) 190 224 
Iron (mg) 1 12 
Magnesium (mg) 151* 86 
Phosphorous (mg) 919* 518 
Potassium (mg) 587* 278 
Sodium (mg) 151 72 
Zinc (mg) 8* 3 
Copper (μg) 
70* 1 
Manganese (μg) 21* 3 
Vitamin B1 (μg) 185* 185 
Vitamin B6 (μg) 80* 62 
Vitamin B3 (μg) 68* 432 
Vitamin B2 (μg) 926* 62 
Table 2-1. Nutritional content of BC and soy supplements.                                                              
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2.2 Participants 
Participants were recruited via presentations to individual rugby clubs in the city of 
Saskatoon, SK, Canada. Only players who were 18 years old or older were allowed to participate 
in the study. Players who had taken other nutritional supplements within the month prior to study 
initiation, and players with milk or soy allergies, were excluded. As part of our screening 
process, participants filled out a “Physical Activity Readiness Questionnaire” (i.e. PAR-Q+, 
Appendix A) form to ensure the physical testing will be safe for them. This form assesses 
participants for medical issues that may place them at risk from exercise testing (Chilibeck et al. 
2011, Warburton et al. 2011). If determined to be at risk, players needed to acquire permission 
from their family physicians to participate in the study. 
Sample size was based on the expected mean change in lean tissue (i.e. muscle) mass with 
BC supplementation (i.e. 1.5kg-2 kg) compared to control (i.e. 0kg-1.2 kg) with a standard 
deviation for this change of 0.5 to 1.0 kg (Antonio et al. 2001; Kerksick et al. 2007), an alpha of 
0.05 and power of 0.8. Although the sample size calculation indicated that 10 participants per 
group (i.e. 20 in total) were required, nine additional participants were recruited to account for 
participants who might withdraw from the study.  
Ethical approval for this study was obtained by the University of Saskatchewan’s 
biomedical research ethics board. Participants were provided with a written and oral overview of 
the study, were given an opportunity to ask questions about the study, and were provided with an 
informed consent form (Appendix B) to read and sign. 
 
2.3 Measurements and Dependent Variables 
The primary outcomes for this study were the mean changes over time, between groups, 
for body composition and strength. Secondary outcomes were the mean changes over time, 
between groups, for vertical jump height, aerobic performance, muscle thickness, and the 
prevalence of upper respiratory tract infections. Measurements for all of these variables were 
obtained prior to the 8 weeks of supplementation (at time of randomization), and 1-3 days after 
the supplementation period. 
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2.3.1 Body composition 
Body composition was assessed with dual energy X-ray absorptiometry (DXA) (QDR 
Discovery Wi; Hologic, Inc., Bedford, MD, USA) using QDR software for Windows XP (QDR 
Discovery, Hologic, Inc.). Fat mass was assessed from whole-body scans. Lean tissue mass was 
assessed from whole-body scans and also from the trunk, arms and legs regions.  The coefficient 
of variation for lean tissue mass is 0.5%, and for fat mass is 3% (Chilibeck et al. 2013). 
 
2.3.2 Strength 
Strength was assessed by performing a one repetition maximum (1RM) on a leg press 
machine and a bench press machine with more than 15 minutes between exercises. The 1RM 
protocol consisted of a 5-8 repetition set with low weight and a 1-min break before the first 1RM 
attempt. Weight was then progressively increased and a 5-3 min rest period was given between 
each subsequent 1-RM attempt. Subjects were permitted four to six attempts to determine their 
1-RM value. This method was previously used in our lab and was described by Chrusch et al. 
(2001). During the leg press 1RM hands were placed on the seat handles the whole time, and the 
back and buttocks kept contact with the seat. A full repetition was only considered when legs 
were fully extended.  
During the bench press 1RM hands were placed approximately shoulder width apart, feet 
were on the floor and the back and buttocks kept contact with the bench the whole time. A full 
repetition was only considered when elbows were fully extended. The coefficients of variation 
for repeated leg press and bench press strength assessments were 3.0% and 3.6%, respectively. 
 
2.3.3 Vertical Jump Height 
We estimated lower body power by a counter movement vertical jump (CMJ) height, using 
the Vertec device for the measurement. Participants stood barefoot and reached up with their arm 
as high as they could, while their heel was still touching the ground. This height was recorded as 
the initial height. Then, participants were given three attempts to jump vertically (with the 
assistance of an arm swing) as high as they could. The highest result from the three attempts was 
recorded. Then, the initial height was subtracted from the maximal height. The coefficient of 
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variation for repeated measures of this test was 1.0% (determined by repeated tests on the 
participants). 
 
2.3.4 Aerobic Performance 
Predicted VO2max was assessed using the Leger maximal multistage 20-m shuttle run field 
test (“the beep test”), where players ran 20m distances at increasing velocity (done to the 
cadence of beeps on a Compact Disc) until exhaustion (Leger and Lambert 1982). A higher 20m 
stage completed indicates a greater aerobic fitness and a higher predicted VO2max. Stages were 
converted to predicted relative VO2max using a conversion table (Leger and Lambert 1982). The 
coefficient of variation for this test is 3.5%. 
 
2.3.5 Markers of immune function 
IgA, CRP, IL-6 and IL-1β levels were analyzed from saliva samples using enzyme-linked 
immunoabsorbent assays (ELISA) by Salimetrics, State College, PA (Appendix C).  
Sample collection was done >60 minutes after eating a major meal. In addition, 
participants were also instructed not to consume alcohol for at least 12 prior to the sample 
collection, as acidic or high sugar foods can compromise assay performance by lowering sample 
pH and influencing bacterial growth.  To minimize these factors, the participants rinsed their 
mouth thoroughly with water 10 minutes before the sample was collected.  Saliva was collected 
from a passive drool through a short straw and into a polypropylene vial. After collection, 
samples were stored in a -20ºC freezer, in order to avoid bacterial growth and loss of immune 
markers in the specimen.   
On day of assay, the samples were thawed completely, vortexed, and centrifuged at 3000 
rpm for 15 minutes.  Centrifuging removes mucins and other particulate matter which may 
interfere with antibody binding, leading to falsely elevated results.  All samples were analyzed in 
duplicate and read in a plate reader at 450nm. The final value taken for each marker was the 
average of the two duplicates from the same sample, when coefficient of variation (CV%) <15.   
If the CV% between the duplicates was higher than 15, the samples were reanalyzed again.  The 
average inter-assay precision (CV%( of 20 replicates for CRP, IL-1β and IL-6 is 5.9%, 2.5% and 
4.8% respectively.  The average inter-assay precision (CV%( of 8 replicates for IgA is 8.79%. 
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Details of the testing kits procedures can be found in Appendix C. 
 
2.3.6 Muscle Thickness 
Muscle thickness was measured using a B-mode ultrasound device (Aloka SSD-500, 
Tokyo, Japan). The muscle thickness sites included the quadriceps and biceps. The quadriceps 
site was land marked on the right leg at 70% of the distance down from the greater trochanter to 
the lateral epicondyle of the tibia. A tape measure was wrapped around the right leg at the 70% 
mark and was used to mark the reference point on the bulk of the vastus lateralis. Participants 
were placed on a table in a seated position with their right leg extended and relaxed. 
 The biceps site was on the bulk of the biceps, approximately two thirds of the way distally 
down the arm between the acromion process of the shoulder and the olecranon of the elbow. 
Participants were instructed to lay their arms as flat as possible on a table so that their arms were 
parallel to the table with their triceps resting.  
All landmarks were mapped using a clear overhead projector sheet to ensure that the sites 
were measured at the same location during the post-test measurement. A water-based gel was 
applied to the 5MHz scanning transducer head to allow for optimal sound wave transmission. 
The transducer was held perpendicular to the skin while avoiding compression of the skin and 
the underlying tissue. An image of the fat/muscle and muscle/bone interface was frozen on the 
display screen for measurement.  For each site, measurements were taken at three different points 
of the site: the proximal, the mid, and the distal, as determined by divisions (1 cm) on the 
monitor. The distal and proximal sites were 6 cm apart, with the mid site located 3 cm between 
them. Muscle thickness was measured from the fat/muscle interface to the muscle/bone interface. 
Measurements were taken to the nearest 0.1 mm. Three measurements were taken at each of the 
three points on each site. An average of these three measurements was taken as the final value. 
The reliability of these ultrasound measurements ranged from a coefficient of variation of 1 to 
3% (Candow and Chilibeck 2005).  
 
2.3.7 Upper respiratory tract infections 
At baseline, the participants were given diaries to track any upper respiratory tract 
infections, flu like symptoms, colds and allergies. The participants were also asked to report the 
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severity (mild, moderate, severe) and the duration of any of the symptoms. The diaries were 
collected and analyzed after 8 weeks. 
 
2.4 Statistical Analysis 
Body composition values, 1RM results, jumps heights, predicted VO2max, salivary 
markers of immune function and inflammation, muscle thickness, dietary variables, training 
volume, baseline characteristics, and average duration of any respiratory tract infections were 
assessed by a group (i.e. BC vs. soy protein) by time (baseline vs. 8 weeks) ANOVA with 
repeated measures on the time factor. If a significant change was found, we used a paired t-test 
for a post-hoc analysis. An ANCOVA was used to assess any outcomes that differed between 
groups at baseline (i.e. baseline scores were used as the co-variate). Statistical significance 
accepted at alpha level ≤ 0.05. All data analyses were performed with IBM SPSS Statistics, 
version 22.0 for Windows. 
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3. Results: 
At baseline, twenty-nine (N=29) participants were randomized (see participants’ 
characteristics- Table 3-1). 5 participants (4 from the BC group, and 1 from the soy group) were 
lost to follow up, and 2 participants (both from the soy group) withdrew due to gastro-intestinal 
distress. Hence, the final per-protocol cohort analysis (Figure 3-1; Table 3-2) included twenty-
two players participants in total (N=22); 11 participants from the BC group, and 11 participants 
from the soy group. At baseline, the two groups were similar (Table 3-1), and there were not any 
statistically significant differences between participants who completed the intervention and 
those who did not complete the intervention (Table 3-3). Means and SD for all dependent 
variables, before and after 8 weeks of supplementation, can be found on Table 3-2.  
 
Table 3-1. Participants’ baseline characteristics (mean ±SD) before 8 weeks of supplementation 
with bovine colostrum (BC) vs. soy protein, during the regular season. 
Group BC (n=15) Soy (n=14) 
# of Females n=2 n=1 
Age (y) 25.7 ±7.0 29.6 ±9.4 
Height (cm) 181.1 ±7.8 179.2 ±8.8 
Weight (kg) 95.6 ±14.2 89.7 ±17.1 
Total lean tissue mass (kg) 67.2 ±9.5 64.5 ±7.9 
Legs lean tissue mass (kg) 21.8 ±3.3 21.2 ±2.6 
Fat mass (kg) 26.2 ±11.2 23.1 ±12.6 
Body fat % 26.2 ±8.7 24.1 ±9.0 
Arm thickness (cm) 4.0 ±0.6 3.8 ±0.5 
Thigh thickness (cm) 4.5 ±0.8 4.0 ±0.8 
1RM bench press (kg) 145.0 ±40.9 131.9 ±26.0 
1RM leg press (kg) 274.0 ±56.8 271.7 ±79.6 
Predicted VO2max (mL/kg/min) 40.9 ±9.2 43.3 ±10.5 
Vertical jump height (cm) 43.0 ±9.3 44.8 ±8.5 
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Per-protocol 
analysis
Follow-up
Allocation
Enrollment
Assessed for eligibility
(N=29)
Randomized 
(N=29)
Allocated to bovine 
colostrum supplementation 
(n=15)
Females (n=2)
Received allocated 
intervention (n=15)
Completed intervention 
(n=11)
Lost to follow-up (n=4)
Analyzed (n =11)
Excluded from 
analysis (n=4)
Lost to follow-up (n=4)
Allocated to soy protein 
supplementation (n=14) 
Females (n=1)
Received allocated 
intervention (n=14)
Completed intervention 
(n=11)
Lost to follow-up (n=1)
Discontinued intervention 
due to GI distess (n=2)
Analyzed (n =11)
Excluded from analysis 
(n=3)
Lost to follow-up (n=1)
GI distress (n=2)
Figure 3-1. Participants flow; per-protocol analysis 
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Dependent Variable Time 
Group 
BC (n=11) Soy (n=11) 
Weight (kg) 
Pre 95.6 ± 14.2 90.7 ± 15.2 
Post 94.7 ± 12.7 89.9 ± 15.7 
Total Lean Tissue Mass (kg) 
Pre 66.7 ± 8.7 65.8 ± 7.1 
Post 66.1 ± 8.1 65.2 ± 7.3 
Legs Lean Tissue Mass (kg) 
Pre 21.8 ± 3.3 21.5 ± 2.2 
Post 21.7 ± 3.3 21.6 ± 2.4 
Total Fat Mass (kg) 
Pre 25.6 ± 12.0 21.5 ± 11.7 
Post 25.2 ± 10.8 21.3 ± 11.8 
Body Fat (%) 
Pre 26.0 ± 10.0 22.6 ± 8.3 
Post 26.0 ± 9.1 22.6 ± 8.5 
Mean Arm Thickness (cm) 
Pre 3.9 ± 0.5 3.9 ± 0.4 
Post 4.1 ± 0.4 4.1 ± 0.3 
Mean Thigh Thickness (cm) 
Pre 4.6 ± 0.8 3.9 ± 0.7 
Post 4.7 ± 0.7 4.2 ± 1.2 
1RM Bench Press (kg) 
Pre 144.2 ± 45.2 139.7 ± 20.8 
Post 145.8 ± 48.4 145.9 ± 24.0 
1RM Leg Press (kg) 
Pre 274.8 ± 65.4 281.6 ± 65.4 
Post 270.5 ± 55.3 268.4 ± 55.3 
Relative VO2max (mL/kg/min) 
Pre 40.6 ± 10.0 43.2 ± 10.6 
Post 43.8 ± 10.8 43.8 ± 10.7 
Vertical Jump Height (cm)  
Pre 42.4 ± 10.1 46.5 ± 8.9 
Post 43.4 ± 9.0 46.0 ± 9.0 
IgA (μg/mL) 
Pre 16.7 ± 282.1 18.3 ± 191.9 
Post 17.1 ± 117.0 18.1 ± 145.6 
IL-1β (pg/mL) 
Pre 230.6 ± 142.4 544.6 ± 810.1 
Post 158.8 ± 128.7 430.0 ± 460.4 
CRP (pg/mL) 
Pre 5034.3 ± 3730 4729.9 ± 5830.7 
Post 1654.4 ± 600.3 3835.0 ± 3864.4 
IL-6 (pg/mL) 
Pre 0.7 ± 0.6 1.6 ± 2.4 
Post 0.3 ± 0.5 1.5 ± 2.8 
 
 
Table 3-2. Means and SD for all dependent variables, before and after, 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season. 
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3.1 Body composition 
There was no significant interaction between time and type of supplementation for total 
lean body mass [Ftime x group (1,20) = 0.002, p=0.964], arms lean body mass [Ftime x group (1,20) = 
0.070, p=0.935], trunk lean body mass [Ftime x group (1,20) = 0.419, p=0.525], legs lean body mass 
[Ftime x group (1,20) = 0.595, p=0.450], total fat mass [Ftime x group (1,20) = 0.138, p=0.715] and body 
fat percentage [Ftime x group (1,20) = 0.008, p=0.929]. Players who consumed BC did not change 
differently across time in comparison to players who consumed soy protein. 
There was a significant main effect of time for total lean body mass which decreased over 
time [Ftime (1,20) = 11.754, p=0.003], and also a significant main effect of time for trunk lean 
body mass which decreased over time [Ftime (1,20) = 5.349, p=0.031]. 
Table 3-3. Baseline Means and SD for all dependent variables for participants who dropped 
out and participants who completed the intervention. 
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3.2 Muscle Thickness 
There was no significant interaction between time and type of supplementation for elbow 
flexors muscle thickness [Ftime x group (1,20)= 0.206, p=0.655] and knee extensors muscle 
thickness [Ftime x group (1,20)= 0.842, p=0.370]. 
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Figure 3-2. Total lean mass (kg) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season. 
Values are means and SD.
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There was a significant main effect of time for elbow flexors muscle thickness 
[Ftime(1,20)= 14.434, p=0.001], which increased over time across participants.  
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Figure 3-4. Elbow flexors muscle thickness (cm) of rugby players, before and after 8 
weeks of supplementation with bovine colostrum (BC) vs. soy protein, during the 
regular season. Values are means and SD.
Elbow flexors thickness before and after 8 weeks of supplementaion
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Figure 3-3. Knee extensors muscle thickness (cm) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season.               
Values are means and SD. 
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3.3 Strength 
There was no significant interaction between time and type of supplementation for bench 
press 1RM [Ftime x group (1,20) = 0.674, p=0.421] and leg press 1RM [Ftime x group (1,20) = 0.36, 
p=0.556]. Players who consumed BC did not change differently across time in comparison to 
players who consumed soy protein. Also, there was no time main effect for strength.  
 
 
 
The relatively high SDs in both strength exercises are probably due to the difference 
between player’s position on the field (i.e., different physiological demands), and their body size 
and weight. 
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Figure 3-5. 1RM Bench Press (kg) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular 
season. Values are means and SD.
1RM Bench Press before and after 8 weeks of supplementaion
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3.4 Vertical Jump Height 
The analysis included twenty participants (N=20), after two participants (one from each 
group) could not complete the post testing for vertical jump due to an injury (could not perform 
shock absorbing movements, such as landing, due to pain).  
ANOVA: There was a significant interaction between time and type of supplementation for 
vertical jump height [Ftime x group (1) =10.58, p=0.004]. Players who consumed BC improved their 
vertical jump over time (+2.5%), in comparison to players who consumed soy protein (Table 3-
2). In a post-hoc analysis, using a paired t-test we found that pre to post scores for the BC group 
were significantly different [F(9)= 4.243, p<0.05], whereas there was no difference for pre to 
post scores for the soy group [F(9)<0.0001 , p>0.05]. Players who consumed BC improved their 
vertical jump over time, in comparison to players who consumed soy protein, with an effect size 
of 0.37. 
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Figure 3-6. 1RM Leg Press (kg) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season.                              
Values are means and SD.
1RM Leg Press before and after 8 weeks of supplementaion
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ANCOVA: To control for baseline differences in vertical jump height, ANCOVA was 
conducted using baseline values as covariates. The analysis revealed that BC supplementation 
improved vertical jump height (adjusted post-intervention mean of 45.3 cm) to a greater extent 
than soy protein supplementation (adjusted post-intervention mean of 42.8 cm) [F (1,17) =8.055, 
p=0.011].  
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Figure 3-7. Vertical jump height (cm) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season.  
Values are means and SD.
*ANOVA p< 0.01; **Post hoc t-test p<0.05 ; ***ANCOVA p=0.01
Vertical jump height before and after 8 weeks of supplementaion
BC
Soy
30 
 
3.5 Aerobic Fitness 
One participant (from the BC group) could not finish the post testing for the Leger 
maximal multistage 20m shuttle run field test (due to an injury), and therefore was not included 
in the analysis (N=21). There was no interaction between time and type of supplementation on 
predicted VO2max [Ftime x group (1,19)=2.256, p=0.126]. On the other hand, there was a significant 
main effect of time, where predicted VO2max increased over time [Ftime (1,19) = 5.796, 
p=0.026].  
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Figure 3-8. Predicted VO2max (mL/kg/min) of rugby players, before and after 8 
weeks of supplementation with bovine colostrum (BC) vs. soy protein, during the 
regular season. Values are means and SD.
Predicted VO2max before and after 8 weeks of supplementaion
BC
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3.6 Markers of immune function 
There was no significant interaction between time and type of supplementation for  
IgA [Ftime x group (1,20) = 1.181, p=0.29], IL-1β [Ftime x group (1,20) = 0.038, p=0.848],  
CRP [Ftime x group (1,20) = 2.402, p= 0.137], or IL-6 levels [Ftime x group (1,20) = 0.037, p=0.848]. 
There was a significant main effect of time for CRP levels [Ftime (1,20) = 7.108, p=0.015],   
with CRP decreasing over time across all participants.  
  
 
Due to a violation of the Levine test for homogeneity of variance (both before and after the 
removal of outliers), a non-parametric Mann-Whitney U-test, was used to verify the effect. No 
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Figure 3-9 .CRP levels (pg/mL) of rugby players, before and after 8 weeks of 
supplementation with bovine colostrum (BC) vs. soy protein, during the regular season. 
Values are means and SD.
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BC
Soy
32 
 
significant difference was found when comparing change scores between the supplement groups 
(U=48.0; p=0.43). 
 
3.7 Upper respiratory tract infections 
No upper respiratory tract infection symptoms were reported throughout the study in either 
group. Only one participant from the BC group reported that in total, he had 3 days with some 
allergy symptoms (irritated eyes, runny nose, sneezing). The same participant also reported that 
he did not have any upper respiratory tract infections symptoms. 
 
3.8 Energy intake 
Two participants did not report their energy intake. Hence, only 20 participants were 
analyzed. There were no differences between groups over time for total energy [Ftime x group 
(1,18)=0.0001, p=0.991], protein [Ftime x group (1,18) = 1.216, p=0.285], carbohydrate [Ftime x group 
(1,18)=0.62, p=0.441] and fat [Ftime x group (1,18) = 0.09, p=0.768] consumption. 
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Table 3-4. Total energy, protein, carbohydrate and fat consumption of rugby players, before and 
after 8 weeks of supplementation with bovine colostrum (BC) vs. soy protein, during the regular 
season. These values do not include the supplement. 
 
 
 
Energy intake 
(Kcal) 
Protein (g) Carbohydrate (g) Fat (g) 
Pre Post Pre Post Pre Post Pre Post 
BC group 
n=10 
3274 
(±557) 
3240 
(±522) 
166 
(± 24) 
 
 ~20.3% 
of total 
calories 
171 
(±20) 
 
~21.1% 
of total 
calories 
340 
(±68) 
 
~41.6% 
of total 
calories 
328 
(±67) 
 
~40.5% 
of total 
calories 
139 
(±33) 
 
~38.2% 
of total 
calories 
138 
(±27) 
 
~38.3% 
of total 
calories 
Soy 
group 
n=10 
3190 
(±307) 
3157 
(±282) 
169 
(±28) 
 
~21.2% 
of total 
calories 
168 
(±22) 
 
~21.3% 
of total 
calories 
349 
(±40) 
 
~43.8% 
of total 
calories 
349 
(±38) 
 
~44.2% 
of total 
calories 
124 
(±24) 
 
~35%  
of total 
calories 
121 
(±20) 
 
~34.5% 
of total 
calories 
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4. Discussion 
The main finding of the current investigation was that BC supplementation in rugby 
players did not significantly improve body composition, strength, aerobic fitness, or immune 
markers level in saliva. A secondary finding of this investigation was that rugby players who 
consumed BC during the season, significantly improved vertical jump height over time, in 
comparison to players who consumed soy protein. This is the first study to our knowledge, to 
show increased vertical jump without any change in body composition and/or strength, in rugby 
players. The vertical jump finding partially supports our hypothesis that the BC group would 
have greater increases in some fitness parameters. The hypothesis for improvement in estimated 
power was based on the evidence that: 12 days of BC supplementation significantly improved 
jump flight times in comparison to placebo supplementation, in athletes (Leppäluoto et al. 2000); 
and that BC supplementation significantly improved peak cycle power and vertical jump height, 
after 8 weeks of resistance and plyometric training (Buckley et al. 2003). 
Successful performance during rugby requires high levels of leg power (which can be 
estimated from vertical jump performance) (Young et al. 1995), particularly for the forwards in 
scrums, rucks and mauls, where the goal is to keep the other team away from the ball (Miller et 
al. 2000; Robinson 2000). The mean pack force during scrummaging ranges from 6210–9090N/ 
~600–1000kg (Quarrie and Wilson, 2000). Vertical jump or leg power per se, would be 
important during lineouts (restarting play after the ball has gone into touch) and kick receiving, 
when players need to jump for the ball. Leg power in general would be important during 
scrummaging, rucking, and mauling when players are pushing against each other. 
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4.1 Body Composition 
In contrast to our original hypothesis, there were no significant changes for either group in 
lean tissue mass, body fat percentage (assessed by DXA) and muscle thickness (assessed by 
ultrasound).  
The absence of significant increases in overall lean body mass is not consistent with one 
study by Antonio et al. (2001), where body mass significantly increased for their whey group, 
but primarily due to an increase in fat mass, while the BC group showed a significant increase in 
lean body mass only, without any significant change in bodyweight. Antonio et al. (2001) used a 
low dosage of only 20g/day, on a non-athlete population, in which body composition changes are 
more likely, in comparison to athletes or the elderly. However, this finding is consistent with a 
previous study in our lab, in which Duff et al. (2014) did not find any significant differences in 
body composition between their two groups of interventions (BC vs. whey supplementation in 
older adults). In addition, Brinkworth and Buckley (2004) also did not find any significant 
differences between groups for upper limb muscle cross-sectional area, after similar 
supplementation and a training regime for the upper limb muscles. Both of the mentioned studies 
used the dosage of 60g/day and were conducted in populations that are less likely to change their 
body composition in a drastic way during 8 weeks only (elderly and pro athletes, respectively). 
The findings of a positive time main effect (increased muscle mass) for elbow flexors, 
together with a negative time effect for total lean body (muscle) mass, may seem to contradict 
each other. However, when analyzing the lean body mass results by region (DXA scans), we 
found that a significant change (p=0.03) was present in the trunk region only. This means that 
players lost most of the total lean body mass from their trunk region, while potentially gaining a 
smaller amount of lean mass in their elbow flexors. 
The negative time main effect for lean body mass, and the positive time main effect on 
aerobic fitness (i.e. decrease in lean tissue mass, but increase in aerobic fitness during our 
intervention), in addition to similar findings by Gabbett (2005) and Schneider et al. (1998), may 
suggest that during in-season rugby training programs, teams tend to put an emphasis on skills 
(catching, ball-carrying, tackling, ball control, etc.), speed, agility, and aerobic training, while 
neglecting strength training. This might be due to the time constraints (Gabbett 2002). 
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This hypothesis should be examined in future research, as the negligence of strength 
training can increase the loss of lean tissue mass and strength, and increase the risk for injuries 
(Gabbett 2005).   
 
4.2 Strength 
In contrast to our original hypothesis, there was not a significant change for either group in 
strength, measured using the 1RM bench press and 1RM leg press. This finding is supported by 
Antonio et al. (2001) who supplemented with 20g/day BC for 8 weeks as well; however, it 
contradicts the finding of a significant difference of strength found by Kerksick et al. (2001), 
who used a dosage of 60g/day of BC in combination with creatine for 12 weeks. These 
differences in the supplement content and the duration of supplementation might be the reason 
for the different result. 
 In addition, our results also contradict the results by Duff et al (2014), who found a 
difference in lower body strength only (leg press 1RM), and no difference in upper body strength 
(bench press 1RM) with BC supplementation. In this case, the different dosage of BC (60g/day) 
and the different population (elderly), might be the reason for the inconsistency in the results. 
 
4.3 Vertical Jump Height 
The significant positive change in vertical jump height, in the BC group, fits our initial 
hypothesis that BC supplementation would improve vertical jump height to a better extent, in 
comparison to soy protein supplementation in rugby players. This significant change in the BC 
group, which may suggest a significant change in lower body power, is the only statistically 
significant finding in our study and it supports previous evidence found by Leppäluoto et al. 
(2000), Hofman et al. (2002), and Buckley et al. (2003).  
It is important to mention that while we found a significant change of 1.1 cm (2.1%) on 
average, the standard error of measurement, using the Vertec device, was found to be 2.1 cm 
(Nuzzo et al. 2011). Hence, this change might be caused by an error of the measurement, may 
not represent a true change, and might be a type 1 error (rejecting the null hypothesis, when it 
should not be rejected). On the other hand, while considering the fact that the participants were 
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amateur athletes, the change magnitude (2.5% in 8 weeks) seems reasonable as Sheppard et al. 
(2009) found a change of only 1.3% in elite volleyball athletes after 12 months of training, and 
Markovic et al. (2007) found a change of 6% in non-athletes after 10 weeks of power training. 
While this statistically significant change in vertical jump (power) was found without a 
significant change in strength or lean tissue mass, we can conclude (assuming that the change 
represents a true change and is not a type 1 error) that: 
i: The aspect of power that was affected by the BC supplementation was velocity (i.e. 
neuromuscular aspects), as power is the product of force (strength) multiplied by velocity. 
While strength is affected by the nervous and the musculoskeletal systems, velocity is 
determined by the nervous system; more specifically, by the functioning of the motor 
cortex (Tyc and Boyajian 2011), cerebellum (Spraker et al. 2012), coordination 
(Almasbakk and Hoff 1996), and other neuromuscular properties such as the rate of force 
development (McLellan et al. 2012).  Although neurological changes seem like the 
possible mechanism, we cannot determine whether these changes accrued in the central 
nervous system or the peripheral nervous system. More research is needed in order to 
decipher the effect of BC supplementation on these neuromuscular aspects and power.                                                                                                                                         
Or that: 
ii: The decrease in total body mass (lean mass + fat mass), while maintaining the same 
level of strength (Table 3-2), could lead to a higher vertical jump height, due to a lower 
gravitational (downward) force that is being applied on the participants (lower body 
weight), resulting in a higher net force upward.  
 
4.4 Aerobic Fitness 
We did not find a significant interaction between the groups of supplementation over time. 
Previous studies found that BC supplementation improves endurance performance. For example, 
Shing et al. (2006) used the same period of time of supplementation in cyclists, and found that in 
a treadmill test to exhaustion, the BC group covered a significantly greater distance and 
completed more work than the whey group and that parasympathetic indices of heart rate 
variability (i.e., increased intervals between two consecutive R waves in the ECG) were elevated 
in the BC group and reduced in the whey group, indicating better cardiovascular functioning 
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with lower heart rate and higher cardiac output in the BC group (2013). Coombes et al. (2002) 
also found that time-trial performance significantly improved in cyclists who were supplemented 
with BC when compared with the whey.   
The mechanism for improvement in endurance performance is unclear and additional 
research is needed in order to determine whether BC supplementation improves endurance 
through the enhancement of nutrient uptake from the intestine, increased muscle glycogen, 
prevention of decreased testosterone, or a different reason. 
 
4.5 Immune Function 
In contrast to our secondary hypothesis, there were no significant interactions between time 
and type of supplementation for any of the immune function markers.  
To our knowledge, this is the first study to measure the effect of BC supplementation on 
CRP concentration in athletes. More research is needed in order to determine whether BC 
supplementation decreases CRP concentration, due to the fact that lower CRP levels in athletes 
can be a beneficial for a faster recovery, better immune functioning and inflammation reduction.  
However, from previous studies one can speculate that BC may influence the immune 
system through the stimulation of cytokine production, as it was shown to: 
 i) Increase cytokine messenger RNA, therefore increased potential for expression of beneficial 
cytokines, in cells of intestinal Peyer’s patches (lymphoid nodules that form an important part of 
the immune system by monitoring intestinal bacteria populations and preventing the growth of 
pathogenic bacteria in the intestines) in weaned piglets (Boudry et al. 2007); and 
ii) Stimulate cytokine secretion from peripheral blood mononuclear cells under resting and 
inflammatory conditions: BC increased the secretion of IFN-Ɣ and IL-10 (anti-inflammatory), in 
resting conditions, and reduced the secretion of TNF and IL-4 (pro-inflammatory cytokines) and 
IL-6 (associated with muscle damage), in a culture rich with lipopolysaccharide (Shing et al. 
2007). These finding suggest that BC may reduce pro-inflammatory cytokine production 
following strenuous exercise, which is associated with elevated lipopolysaccharide 
concentrations. Increased circulating lipopolysaccharide levels in humans, lead to various 
symptoms, such as fever, shivering, dizziness, nausea, various gastro-intestinal complaints such 
as vomiting and diarrhoea, and ultimately sepsis (Jeukendrup et al. 2000). 
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Lastly, based on the literature and the possible increase in salivary IgA concentration, we 
also hypothesized that BC supplementation would reduce respiratory tract infections. But, as we 
did not have any cases of respiratory tract infection symptoms, we could not perform an analysis.  
The reason for the lack of upper respiratory tract infections might be due the winter seasonality 
of more than 200 different viruses (e.g: influenza, paramyxoviruses, parainfluenza, 
coronaviruses, picornaviruses) that cause upper respiratory tract infections (Collier and Oxford, 
2000), and the fact that our intervention was done during the summer months. 
 
4.6 Strengths, Limitations and Future Research 
Other than being the first study, to our knowledge, to examine the effect of BC 
supplementation in rugby players, this study had a strong design (i.e. double blind, active 
comparator, and randomized). Moreover, our study had multiple outcomes while presenting a 
small amount of risks and side effects (only 2 cases were reported in total; both in the soy group, 
and led the participants to withdraw). Our outcomes were measured in valid, reliable and non-
invasive methods such as the DXA scan, that has a coefficient of variation for lean tissue mass of 
0.5% (Chilibeck et al. 2013), and the B-mode ultrasound which is a sensitive method to measure 
muscle thickness and had been validated in comparison to MRI, for the assessment the knee 
extensors (Miyatani et al., 2002) and elbow flexors (Miyatani et al., 2000) - the two muscle 
groups that were assessed in our current study. 
The supplements that were used in the study were flavorless and odorless, with the same 
color and texture, and caused low amount of side effects. We have used an absolute dose (in 
contrast to relative dose) as all previous studies have done it, and comparison of the effect would 
fit better. Also, using a fixed dose is usually prescribed when supplements are sold in store (this 
might be a limitation, because participants with a smaller body size, were to receive a larger 
relative dose). These, in addition to the sensible daily dose of the supplement, might have 
contributed the low amount of side effects.  
On the other hand, our study had some limitations. One of them is the use of soy protein as 
the control. As whey is more “similar” to BC, and has a better amino acid profile, it would 
probably be a better comparator than soy.  
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In addition, the sex distribution of the participants was not equal, with only 3 females out 
of a total of 29, making it difficult to determine effects of gender. In future research it would be 
of benefit to include more women, especially given that rugby is now a men’s and women’s 
sport at the Olympics. There will therefore be increased need for research on both men’s and 
women’s rugby. 
While the advantage of per-protocol analysis is that it better reflects the effects of the 
intervention (Piaggio et al. 2006), it can lead to bias and poor generalizability. Therefore, another 
limitation in our study is increased chance for a type 1 error, associated with measuring and 
analysing multiple outcomes, and the use of per-protocol analysis, which excludes participants 
who did not complete the protocol (i.e., if the reason for the “lost to follow-up” participants was 
side effects of the supplement, we might erroneously conclude that the supplement was effective 
because the remaining participants might have tolerated the supplement and improved their 
different dependent variables). We were not able to obtain measurements from the 2 participants 
who dropped out of the study (due to gastro-intestinal distress) as they were not able to arrive to 
our lab on any of the days that we have suggested for post-interception measurements. The 
advantage of per-protocol analysis is that it better reflects the effects of the intervention (Piaggio 
et al. 2006), but it can lead to bias and poor generalizability. 
Although we did find a significant difference in vertical jump height, we cannot determine 
the mechanisms by which BC supplementation affects power, as we did not use any neurological 
tests and made no assessment of muscle quality. Future research could use neurological tests that 
would test variables such as peak power, average power, rate of force development, 
coordination, EMG, tests of motor unit recruitment (e.g: interpolated twitch technique), etc. The 
power assessment should also include upper body power, using a movement such as explosive 
push-up on a force plate, in order to test if the improvement in power is in the lower body only, 
or has an all-around effect. In addition, future training programs of the participants should focus 
on the main dependant variable that is being measure. i.e., while assessing power, a training 
program that focuses on the enhancement of strength and power, would be more suitable; and 
while assessing aerobic fitness, a training program that focuses on the enhancement of aerobic 
training, would be more suitable. Also, using a cross-over design could be used to measure the 
difference within the athletes, instead of between the randomized groups, decreasing amount of 
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variability in analyses. This design would take longer and need a washout period in between the 
two types of supplementation in order to prevent a carry-over effect. 
While saliva sampling is a quick, non-invasive, “friendly” process, it may have some 
disadvantages (in comparison to human serum). For instance, the levels of IL-6, IL-1β and CRP 
levels are much lower in saliva than in human serum: 
 Mean IL-6 levels in serum is 13.7 pg/mL vs. 1.27 pg/mL in saliva (Arican et al. 
2005). 
 Mean IL-1β levels in serum is 110 pg/mL vs. 8 pg/mL in saliva (Ozeren et al. 
2003). 
 Mean CRP levels in serum is 5x105 pg/mL vs. 1300 pg/mL in saliva (Clyne and 
Olshaker, 1999). 
Moreover, the salivary immune markers levels can be impacted by eating, drinking, and other 
environmental and behavioral conditions. These can affect the reliably and accuracy of the 
results.  
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5. Summary and Conclusions 
The current research was the first to assess the effect of 8 weeks of BC supplementation on 
rugby players’ fitness and immune function, during the regular rugby season. The study main 
finding was that BC supplementation did not significantly change body composition, strength, 
aerobic fitness and levels of salivary immune markers, in rugby players, in comparison to soy 
protein. 
A secondary finding of this work is the significant improvement in vertical jump height, 
which may suggest improvement in lower body power, in the BC group, in comparison to the 
control group (soy protein).  
More research is needed in order to: i) Determine if BC supplementation significantly 
improves power in athletes; ii) Find the potential mechanism/s for this effect; and iii) Determine 
BC supplementation’s effect compared to other common protein supplements. 
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APPENDIX B: Consent Form 
 
Participant Information and Consent Form 
 
Title: The effect of bovine colostrum and soy protein supplementation on fitness, muscle 
mass, inflammation and immune function during intense training in rugby players 
Principal Investigator: Philip D. Chilibeck, Ph.D., Professor, College of Kinesiology, 
University of Saskatchewan, phone: 306-966-1072 
Student Researcher: Eliran Mizelman, B.Sc., (M.Sc. student supervised by Philip Chilibeck), 
College of Kinesiology, University of Saskatchewan, phone: 306-966-1123 
Sponsors: Mitacs Accelerate Program and the Saskatoon Colostrum Co. Ltd. 
Emergency Telephone Number: 306-230-3849 
Introduction 
You are invited to take part in this research study that involves nutritional supplementation with 
bovine colostrum or soy protein during your rugby season. Bovine colostrum is the milk that is 
secreted by cows during the first day after calving. The bovine colostrum and soy protein 
supplements we are using for this study are commercially available. 
Your participation is voluntary. It is up to you to decide whether or not you wish to take part. If 
you decide to participate, you are still free to withdraw at any time and without giving any 
reasons for your decision. If you do not wish to participate, you will not affect your relationship 
with the researchers, the university, or your coaches. 
Please take time to read the following information carefully. You can ask the study staff to 
explain any information that you do not clearly understand. You may ask as many questions as 
you need. Please feel free to discuss this with your family, friends or family physician before you 
decide. 
Who is conducting the study? 
The study is being funded by the Saskatoon Colostrum Co. Ltd. with matching funds from 
Mitacs, which is a government funding organization that supports research that collaborates with 
industry. The sponsors of this study will reimburse the investigators and university for the cost of 
undertaking this study. 
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Why is this study being done? 
This study is being done because we want to determine the effect of soy protein and colostrum 
protein supplementation during your rugby season and their effects on muscle mass, strength, 
aerobic performance, and immune function.  
Who can participate in this study? 
You are eligible to participate in this study if you are male or female training on a regular basis 
with a rugby club and 18y or older. We will determine whether the exercise testing we will be 
doing is safe for you by having you fill out a brief questionnaire (the Physical Activity Readiness 
Questionnaire). If there is doubt about the safety of the exercise testing for you based on this 
questionnaire, we will need to get permission from your family physician, with your approval, 
before you can participate in this study. You should not participate in this study if you have 
allergies to milk or soy. 
What does the study involve? 
The study involves consuming either the bovine colostrum or soy protein supplement. If you 
agree to participate in the study you will be randomly assigned (i.e. by chance by a computer) to 
a group that receives 60 grams per day bovine colostrum supplement or 60 grams per day soy 
protein. You will have a 50% chance of being assigned to either group. You will be required to 
consume the protein supplement combined with water, milk, or juice three times per day. On 
training days, you will consume the supplement before and after your training sessions and then 
once with a meal. On days when you are not training you will consume the supplement 3 times 
per day with meals. The study is “double blind” which means that neither you nor the study 
personnel will know what supplement you are receiving until the end of the study. In case of 
emergency however, we can find out which supplement you are on. 
Before and after the 8 week protein supplementation we will do the following assessments on 
you: 
1) Lean tissue and fat mass will be assessed with dual energy X-ray absorptiometry by a nuclear 
medicine technologist in the RJD Williams Building at the University of Saskatchewan (221 
Cumberland Ave North, Room 108). This involves lying on a table while you are scanned with 
an X-ray. This test takes about 10 minutes. 
2) The size of the muscles at the front and back of your upper arms and legs will be assessed by 
ultrasound by a Kinesiology research assistant at the RJD Williams Building (221 Cumberland 
Ave. North, Room 108). This involves placing a gel on your skin and placing a probe over the 
gel. The probe emits sound waves that allow assessment of the thickness of your muscles. This 
will take about 20 minutes. 
3) Your power and strength will be determined by assessing your vertical jump performance and 
the maximal amount of weight you can lift during a “bench press” exercise and a “leg press” 
exercise. The vertical jump test requires you to jump as high as you can. This test will be 
repeated three times, with your highest jump recorded. The bench press involves lying on a 
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bench and pushing a weight up from chest level. The leg press involves pushing a weight with 
your feet while extending your legs. You will initially be given a warm-up on an exercise bike, 
following by light stretching, and lifting light weights on the bench press and leg press. This 
power and strength testing will take about 25 minutes. This will be supervised by a Kinesiology 
research assistant at the RJD Williams Building (221 Cumberland Ave. N., Room 108). 
4) We will get you to “drool” into a collection container so we can analyze your saliva for 
proteins involved in immune function and inflammation. This takes about 5 minutes. 
5) You will be required to perform an aerobic exercise test. This involves running between two 
cones placed 20 m apart at a pace that gradually increases. The pace at which you run will be 
indicated by “beeps” emitted from a CD player. The test ends when you cannot keep pace with 
the beeps. This test will last between six and 15 minutes, depending on your aerobic fitness (the 
test will be longer if you have a higher aerobic fitness). This testing will be done in the RJD 
Williams Building (221 Cumberland Ave. N, 2nd floor gymnasium). 
6) You will be required to keep a record of all the foods and beverages that you consume over a 
3 day period. This will be done during the first week and last week of your supplementation. The 
purpose of this food and beverage diary is so that we can monitor the influence of any foods and 
beverages you consume on changes in your strength and muscle mass. 
7) You will be required to keep a log of your rugby training and games played and any other 
training you do outside of rugby practices. 
8) You will be required to keep a record of any colds you catch during the 8-week study. You 
will need to indicate the number of colds you catch and the number of days the cold lasts. 
All testing (except the food diaries, training logs, and records of any colds) will be done during 2 
study visits – one at baseline (i.e. before the supplementation program) and one after the 8-week 
supplementation program. We anticipate that each of these visits for measurements will last 
between 75 and 90 minutes. 
There will be a total of 36 participants in this study at the University of Saskatchewan. 
 
What are the benefits of participating in this study? 
You may increase your muscle mass, strength, and aerobic performance by participating in this 
study. These benefits are not guaranteed. 
What are the possible risks and discomforts? 
Bovine colostrum supplementation: In a previous study of older individuals taking the same dose 
of colostrum, 10% of participants reported mild gastro-intestinal symptoms that included 
bloating, nausea, and diarrhea. These adverse events were not severe enough for the participants 
to stop taking the supplement. 
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The exercise testing may result in muscle pulls or strains, or muscle soreness. You will be given 
a proper warm-up prior to exercising testing and qualified exercise trainers will supervise testing 
sessions.  
The ultrasound measurements may involve discomfort as the gel used might feel cold. 
There is a small amount of radiation exposure from the dual energy X-ray scans. This is equal to 
one tenth of the amount of radiation you would receive from taking a trans-Atlantic flight from 
North American to Europe, or less than 0.5% from what you would receive from a routine full-
mouth dental X-ray. 
What are alternatives to the study? 
You do not have to participate in this study to receive the nutritional supplements. The 
nutritional supplements being evaluated in this study are available at health food stores. 
What happens if I decide to withdraw? 
Your participation in this research is voluntary. You may withdraw from this study at any time. 
You do not have to provide a reason. Your relationships with the researchers, the university, or 
your coaches will not be affected.  
If you choose to enter the study and then decide to withdraw at a later time, all data collected 
about you during your enrolment will be retained for analysis.  
What happens if something goes wrong? 
In the case of a medical emergency related to the study, you should seek immediate care and, as 
soon as possible, notify the principal investigator. Inform the medical staff you are participating 
in a clinical study. Necessary medical treatment will be made available at no cost to you. By 
signing this document, you do not waive any of your legal rights against the sponsor, 
investigators or anyone else. 
 
What happens after completion of the study? 
We will inform you of the overall study results after we have analyzed all data (approximately 
September 2014). 
What will the study cost me? 
You will not be charged for the study supplements or any research-related procedures. You will 
not be paid for participating in this study. Reimbursement for study-related expenses (e.g. travel, 
parking) is not available. 
There is a possibility the results of the study might be commercialized to promote the protein 
supplements. You will not receive any financial benefit from this commercialization. 
Will my participation be kept confidential? 
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In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy of your 
personal health information must be maintained so that your privacy will be respected. Your 
name will not be attached to any information, nor mentioned in any study report, nor be made 
available to anyone except the research team.  It is the intention of the research team to publish 
results of this research in scientific journals and to present the findings at related conferences and 
workshops, but your identity will not be revealed. 
Who do I contact if I have questions about the study? 
If you have any questions or desire further information about this study before or during 
participation, you can contact Philip Chilibeck at 306-966-1072 or phil.chilibeck@usask.ca 
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board, at 306-966-2975 (out of town calls 1-888-966-2975). The Research Ethics Board is 
a group of individuals (scientists, physicians, ethicists, lawyers and members of the community) 
that provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
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CONSENT TO PARTICIPATE 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I have been informed of the alternatives to the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I am free to withdraw from this study at any time for any reason and the decision to stop 
taking part will not affect my future relationships at the university, or with my coaches. 
o I agree to follow the principal investigator's instructions and will tell the principal 
investigator at once if I feel I have had any unexpected or unusual symptoms. 
o I have been informed there is no guarantee that this study will provide any benefits to me.  
o I give permission for the use and disclosure of my de-identified personal information 
collected for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my legal rights.  
o I will be given a signed and dated copy of this consent form. 
o If required, my family physician can be consulted regarding my health and participation in 
this study. 
  Yes, you may contact my primary care physician  
  No, please do not contact my primary care physician 
  I do not have a primary care physician. 
 
o  I agree to participate in this study: 
 
Printed name of participant:     ______________________                  
Signature  _______________________      Date___________________________  
Printed name of person obtaining consent: _____________________       
Signature  _________________________ Date___________________________  
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APPENDIX C: Salivary Immune Markers ALISA Kits 
CRP 
 
SALIVARY C-REACTIVE PROTEIN 
For Research Use Only 
Item No. 1-3302, (Single) 96-Well Kit; 
1-3302-5, (5-Pack) 480 Wells 
Updated: February 26, 2014 
Salimetrics, LLC 
101 Innovation Blvd., Suite 302 State College, PA 16803, USA 
(T) 814-234-7748, (F) 814-234-1608 
800-790-2258 (USA & Canada only) www.salimetrics.com 
support@salimetrics.comSalimetrics Europe, Ltd. 
Unit 7, Acorn Business Centre 
Oaks Drive, Newmarket 
Suffolk, CB8 7SY, UK 
(T) +44 (0) 1638782619, (F) +44 (0) 1638782606 info@salimetricseurope.com 
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Intended Use 
The Salimetrics™ CRP kit is an enzyme-linked immunoassay specifically designed and validated for the 
quantitative measurement of salivary CRP.  It is not intended for diagnostic use.  It is intended only for 
research use.   
Please read the complete kit insert before performing this assay.  Failure to follow kit procedure and 
recommendations for saliva collection and sample handling may result in false values.   
For further information about this kit, its application, or the procedures in this insert, please contact the 
technical service team at Salimetrics or your local sales representative. 
Introduction 
C-reactive protein (CRP) is the best-known member of a group of acute-phase proteins, which increase 
their concentrations during certain inflammatory disorders.  CRP is widely used as a bio-marker of 
inflammation in the body. 
Most CRP is produced in the liver, and increased production during the acute phase is induced 
principally by the cytokine interleukin-6 (IL-6), operating primarily at the level of transcription. (1) IL-6  is 
released by a variety of tissues, including activated leukocytes, adipocytes, and endothelial cells. (2,3)  In 
turn, CRP is capable of binding to and modulating the function of monocytes, enhancing their capacity 
to produce inflammatory cytokines, including IL-6. (4,5)  CRP binds to phosphocholine, a common 
constituent of polysaccharide coatings of bacterial pathogens and of cell membranes.  This allows it to 
function as an opsonin, facilitating phagocytosis of pathogens and dead or dying cells. (1,5)  Other 
functions of CRP include activating the classical complement pathway,  activating  macrophage 
tumoricidal activity, and protecting against septic shock. (5)   
CRP levels in humans are normally quite low, but they increase several hundred fold during the acute-
phase response.  Elevated serum CRP levels have been associated with the presence of cardiovascular 
disease.  (6,7)  Numerous recent research studies investigating serum CRP and its relationship to other 
diseases have also been carried out.  These include hypertension, (8,9) diabetes, (2,10) cancer, (11) and 
autoimmune disorders. (12)  Recent literature suggests possible links between oral health and chronic 
infection, inflammation, and heart disease. (13)   Studies have also linked elevated serum CRP levels to 
oral contraceptive use.  
(14,15)   
Recent studies have begun to examine the relationship between salivary and serum CRP.  One study 
reported a moderate to strong association between CRP measured in saliva and in serum, while a 
second longitudinal study found that salivary and plasma CRP were moderately associated cross-
sectionally and across two years. (16,17) 
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Test Principle 
A microtitre plate is coated with mouse antibodies to human CRP.  CRP in standards and unknowns and 
goat anti-human CRP antibodies linked to horseradish peroxidase are added.  A “sandwich” is formed 
with the pre-coated antibody on the bottom, the CRP in the middle, and the antibody linked to 
horseradish peroxidase on the top.  After incubation, unbound components are washed away.  Bound 
CRP peroxidase is measured by the reaction of the peroxidase enzyme on the substrate 
tetramethylbenzidine (TMB).  This reaction produces a blue color.  A yellow color is formed after 
stopping the reaction with 2-molar sulfuric acid.  Optical density is read on a standard microplate 
reader at 450 nm.  The amount of CRP peroxidase detected is directly proportional to the amount of 
CRP present. (18) 
Calculations 
1. Compute the average optical density (OD) for all duplicate wells. 
2. Plot the reference standard concentrations on the X axis and the corresponding average optical 
density on the Y axis. 
3. Using the average optical density values of the controls and unknowns, determine the corresponding 
concentration of CRP in pg/mL from the standard curve.  We recommend using a linear curve fit.  
4. Multiply the calculated concentrations by the dilution factor of 10 to obtain final CRP concentrations 
in pg/mL.   
5. Samples with CRP values greater than 3000 pg/mL should be diluted with CRP sample diluent and 
rerun for accurate results.  If an addi     tional dilution of the sample is used, multiply the results by 
the dilu     tion factor.   
Salivary CRP Example Values from Healthy Adults,   
Aged 20-54 Years* (16) 
N 
Mean (pg/mL)  Std Error of  
Mean (pg/mL)  
Range 
 (pg/mL) 
51 1293.28 140.61 113.69 - 
6131.40 
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Intended Use 
The Salimetrics™ SIgA kit is an indirect competitive immunoassay designed and validated for the 
quantitative measurement of SIgA in saliva samples. It is intended only for research use in humans and 
some animals. 
Please read the complete kit insert before performing this assay. Failure to follow kit procedure and 
recommendations for saliva collection and sample handling may result in false values.  
For further information about this kit, its application, or the procedures in this insert, please contact the 
technical service team at Salimetrics or your local sales representative. 
Introduction 
Secretory immunoglobulin A (SIgA) is the dominant immunoglobulin in external secretions that bathe 
mucosal surfaces (respiratory, intestinal, and reproductive), where it acts as a key component of  the 
immune system’s “first line of defense” against microbial invasion. (1,2) Dimeric IgA secreted by 
mucosal plasma cells adjacent to the salivary glands is bound and transported through the salivary cells 
by a polymeric Ig receptor (pIgR). The IgA dimer, in complex with a fragment of the pIgR polypeptide, is 
then released into saliva as secretory IgA (SIgA). (2,3) 
IgA-producing plasma cells are generally undetectable in the mucosae before 10 days of age, but they 
increase rapidly thereafter. (1) SIgA levels are generally thought to be very low in newborn infants and 
to rise quickly during the first month of life. (4,5,6) Levels of salivary SIgA continue to increase as 
children age, stabilizing within the adult range around 5-7 years. (6,7,8) Reports of changes in SIgA 
secretion in old age are inconsistent, with both increases and decreases having been observed. (9,10)  
Relative numbers of IgA-producing plasma cells are higher in the submandibular and sublingual glands 
compared to the parotid glands, and even higher in certain minor glands, leading to differing levels of 
SIgA in the secretions from these glands. It is speculated that greater density of plasma cells in certain 
glands may be due to increased antigenic interactions in those parts of the mouth. (3) 
The active transport mechanism into saliva for SIgA serves as a ratelimiting factor, (2) and salivary 
levels of SIgA decrease as flow rates increase. (7,10) The contributions to whole saliva from the various 
salivary glands in the mouth also vary greatly according to the rate of flow. (3) The literature therefore 
recommends that variability in salivary flow rate should be taken into account when estimating salivary 
levels of SIgA and making comparisons between individuals. (2,3,7)  
Salivary SIgA levels vary in a complex fashion in response to stress, mood, and emotionality. (2) 
The present enzyme immunoassay protocol represents a significant advance over the traditional SIgA 
measurement approach to employing single radial immunodiffusion (SRID). This enzyme immunoassay 
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is designed to capture the full range of salivary SIgA levels and uses only 25 μl of saliva per test, with 
minimal incubation times. 
Test Principle 
A constant amount of goat anti-human SIgA conjugated to horseradish peroxidase is added to tubes 
containing specific dilutions of standards or saliva. The antibody-conjugate binds to the SIgA in the 
standard or saliva samples. The amount of free antibody remaining is inversely proportional to the 
amount of SIgA present. 
 
After incubation and mixing, an equal solution from each tube is added in duplicate to the microtitre 
plate coated with human SIgA. The free or unbound antibody-conjugate binds to the SIgA on the plate. 
After incubation, unbound components are washed away. Bound conjugate is measured by the reaction 
of the peroxidase enzyme on the substrate tetramethylbenzidine (TMB). This reaction produces a blue 
color. A yellow color is formed after stopping the reaction. Optical density is read on a standard plate 
reader at 450 nm. The amount of peroxidase is inversely proportional to the amount of SIgA present in 
the sample. (11) 
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Typical Results 
The results shown below are for illustration only and should not be used to calculate results from 
another assay. 
Well  Sample  
Average  
OD  B  B/Bo  
SIgA 
(μg/mL)  
A1,A2  S1  0.140  0.130  0.079  600.0  
B1,B2  S2  0.313  0.303  0.185  200.0  
C1,C2  S3  0.526  0.516  0.314  66.7  
D1,D2  S4  0.970  0.960  0.585  22.2  
E1,E2  S5  1.326  1.316  0.801  7.4  
F1,F2  S6  1.509  1.499  0.913  2.5  
G1,G2  Bo  1.652  1.642  NA  0  
H1,H2  NSB  0.010  NA  NA  NA  
 
Salivary SIgA Example Range* 
Group  Number Range (μg/mL)  Mean (μg/mL)  Std Dev (μg/mL)  
Adults  21 93.2-974.03  379.39  261.47  
*To be used as a guide only. Each laboratory should establish its own range. 
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SALIVARY IL-6 ELISA KIT  
  
  
Intended Use  
  
The Salimetrics™ IL-6 kit is a sandwich immunoassay specifically designed for the quantitative 
measurement of salivary IL-6.  It is not intended nor validated for diagnostic use. It is intended only for 
research use in humans.   
Please read the complete kit insert before performing this assay. Failure to follow kit procedure and 
recommendations for saliva collection and sample handling may result in false values.  
For further information about this kit, its application, or the procedures in this insert, please contact the 
technical service team at Salimetrics or your local sales representative.  
  
Introduction  
  
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in a multitude of inflammatory responses with roles 
in immune regulation [1,2] and pathologic conditions including both acute and chronic inflammatory 
diseases [3].  IL-6 initiates and up-regulates inflammation, triggers the release of acute phase proteins, 
regulates inflammatory response, attracts immune cells to sites of injury or infection and stimulates 
coagulation [4].  Salivary levels have varying correlations to serum levels depending on the research 
applications [5, 6].  
Test Principle  
A microtitre plate is coated with mouse antibodies to IL-6.  IL-6 in standards and unknowns attach to the 
antibody binding sites. After incubation, unbound components are washed away. Biotin conjugated to 
goat antibodies to human IL-6 are added and attach to the bound IL-6. After incubation, unbound 
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components are washed away. Streptavidin conjugated to horseradish-peroxidase (HRP) is added and 
binds to the biotin conjugated to the goat antibodies. Bound streptavidin-HRP is measured by the 
reaction of the HRP enzyme on the substrate tetramethylbenzidine (TMB). This reaction produces a blue 
color. A yellow color is formed after stopping the reaction with 2-molar sulfuric acid. Optical density is 
read on a standard plate reader at 450 nm. The amount of streptavidin-HRP detected is proportional to 
the amount of IL-6 present.     
Typical Results  
 The results shown below are for illustration only and should not be used to calculate results from 
another assay.  
 
  
 
Well  Sample  Average OD  IL-6 (pg/mL)   
A1,A2  S1  
1.719  
100.0  
B1,B2  S2  
0.888  
50.0  
C1,C2  S3  
0.459  
25.0  
D1,D2  S4  
0.240  
12.5  
E1,E2  S5  
0.133  
6.25  
F1,F2  S6  
0.078  
3.125  
G1,G2  S7  
0.053  
1.56  
H1,H2  0  
0.028  
0.0  
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Limitations  
  
• Samples with IL-6 values greater than 100 pg/mL (or greater than 500 pg/mL after multiplying 
by the factor of 5 in Step 3) should be diluted further with IL-6 Sample Diluent and rerun for 
accurate results.  Multiply the results by the dilution factor.    
• See Specimen Collection recommendations to insure proper collection of saliva specimens and 
to avoid interfering substances.  
• Samples collected with sodium azide are unsuitable for this assay.  
• Avoid more than 2 freeze-thaw cycles after the initial freeze/thaw.  
Salivary IL-6 Example Ranges*  
Nineteen adult subjects of presumably good health collected their own saliva during the day.  Samples 
were frozen within 4 hours.  The samples were tested in duplicate with the Salimetrics Salivary IL-6 ELISA 
Kit.  
  
Salimetrics IL-6 ELISA Kit   
  
N  Median 
(pg/mL)  
Min 
(pg/mL)  
Max  
(pg/mL)  
Adult Passive Drool  19  1.27  0  5.37  
      
*To be used as a guide only.  Each laboratory should 
establish its own range. 
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Intended Use 
The Salimetrics™ IL-1β kit is a sandwich immunoassay specifically designed for the quantitative 
measurement of salivary IL-1β.  It is not intended nor validated for diagnostic use.  It is intended only 
for research use in humans.  
Please read the complete kit insert before performing this assay.  Failure to follow kit procedure and 
recommendations for saliva collection and sample handling may result in false values.  
For further information about this kit, its application, or the procedures in this insert, please contact the 
technical service team at Salimetrics or your local sales representative. 
Introduction 
IL-1β is a key pro-inflammatory cytokine that is released after infection, injury, or antigenic challenge.  It 
has been widely studied for its role as a multi-functional signaling molecule that affects nearly all cell 
types, either alone or in combination with other pro-inflammatory cytokines.  
(1,2) 
Circulating IL-1β is principally produced by activated macrophages, but it is also secreted from a wide 
variety of epidermal, epithelial, lymphoid, and vascular tissues. (1,2)  IL-1β is also present in the saliva of 
both healthy and diseased individuals.  In the oral cavity, the sources of IL-1β production include 
macrophages, monocytes, fibroblasts, and mucosal epithelial cells. (3,4)  IL-1β has also been reported to 
be synthesized  
and released from acinar and ductal cells in mouse salivary glands. (57)  Human tear fluid and gingival 
crevicular fluid (GCF), which may be present as components of whole saliva, also contain IL-1β. (8,9)    
Salivary IL-1β has been reported to have a circadian rhythm with highest levels in the morning (after 
waking) and lowest levels in the evening. (10-12) This is the opposite of the pattern seen in serum, 
where peak levels occur from 1-4 AM and daytime levels are low. (13)  
Levels of IL-1β in saliva and GCF have been studied in relation to gingival and periodontal disease, and 
significant correlation to the presence of periodontal disease has been found. (8,14-19)   
Levels of IL-1β in saliva and GCF have been observed to change in response to various types of physical 
and psychological stressors, similar to the response to seen in the circulation. (10,20-22)  
The relationship between salivary and circulating levels of IL-1β is not clear.  Serum or plasma levels of 
IL-1β in healthy individuals are very low and often below the limit of detection. (1,23,24)  IL-1β levels 
are generally higher in saliva than in plasma or serum. (23,25)  One study has reported that the 
correlation between human passive drool saliva samples and plasma for IL-1β is not statistically 
significant. (26) 
84 
 
Test Principle 
A microtitre plate is coated with mouse antibodies to IL-1β.  IL-1β in standards and unknowns attach to 
the antibody binding sites.  After incubation, unbound components are washed away.  Biotin conjugated 
to goat antibodies to human IL-1β are added and attach to the bound IL-1β.  After incubation, unbound 
components are washed away.   
Streptavidin conjugated to horseradish-peroxidase (HRP) is added and binds to the biotin conjugated to 
the goat antibodies.  Bound streptavidin-HRP is measured by the reaction of the HRP enzyme on the 
substrate tetramethylbenzidine (TMB).  This reaction produces a blue color.  A yellow color is formed 
after stopping the reaction with 3-molar sulfuric acid.  Optical density is read on a standard plate reader 
at 450 nm.  The amount of streptavidin-HRP detected is proportional to the amount of IL-1β present. 
(27)  
Typical Results    
The following results are shown for illustration only and should not be used to calculate results from 
another assay. 
 
 
Well Standard Average OD IL-1β (pg/mL) 
A1,A2 S1 2.001 200 
B1,B2 S2 1.051 100 
C1,C2 S3 0.556 50 
D1,D2 S4 0.290 25 
E1,E2 S5 0.159 12.5 
F1,F2 S6 0.088 6.25 
G1,G2 S7 0.056 3.13 
H1,H2 Zero 0.021 0 
Salivary IL-1β Example Ranges* 
Group N Mean 
(pg/mL) 
Mean (x15  
Dilution)  
(pg/mL) 
Standard  
Deviation  
(pg/mL) 
Mean  
adjusted for 
flow rate  
(pg/min.) 
Correlation of Mean  
(x15 Dilution) to  
Flow Rate 
  Adults 27 8 122 138 72 -0.184 
     *To be used as a guide only.  Each laboratory should establish its own range. 
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APPENDIX D: Instructions for Using the Supplement 
Study: The effect of bovine colostrum supplementation 
on fitness, muscle mass, inflammation and immune 
function during intense training in rugby players. 
 
Directions for use 
 
• Fully mix or blend 1 level scoop of powder into 4 to 8 
oz. (1/2 to 1 cup) of smoothie, juice or water. 
 
• Consume 3 level scoops of powder daily for 8 weeks. 
 
• On days when you train, consume 1 scoop before 
your training session, 1 scoop after your training 
session, and 1 scoop with a meal. On days you don't 
train consume 1 scoop three times during the day 
with meals. 
 
 
For any questions or concerns please call: 
 
Phil @ 306-966-1072, OR 306-230-3849 
Eliran @ 306-261-2345 
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APPENDIX E: Bovine Colostrum Product Information  
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APPENDIX F: Statistical Tables 
Body composition (DXA) 
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Total Fat mass 
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Weight 
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Muscle Thickness (U.S) 
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Strength 
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Vertical Jump 
ANOVA: 
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Post-hoc: 
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ANCOVA: 
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Aerobic Fitness 
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Markers of Immune Function 
 
 
 
 
 
 
 
 
 
 
 
Non parametric Mann-Whitney U-test 
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Energy Intake 
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